Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dong-Wan Kim, Myung-Ju Ahn, Yuankai Shi, Tommaso Martino De Pas, Pan-Chyr Yang, Gregory J. Riely, Lucio Crinò, Tracey L. Evans, Xiaoqing Liu, Ji-Youn Han, Ravi Salgia, Denis Moro-Sibilot, Sai-Hong Ignatius Ou, Scott N. Gettinger, Yi Long Wu, Silvana Lanzalone, Anna Polli, Shrividya Iyer, Alice Tsang Shaw
Institutions: Seoul National University Hospital, Samsung Medical Center, Sungkyunkwan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, European Institute of Oncology, National Taiwan University Hospital, Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera di Perugia, Abramson Cancer Center, University of Pennsylvania, Academy of Military Medical Sciences, National Cancer Center, National Cancer Center Hospital, University of Chicago, Centre Hospitalier Universitaire de Grenoble, University of California, Irvine, Yale University, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Pfizer (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2594800725